|
Abnormal behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.
|
19320528 |
2009 |
|
Acquired Immunodeficiency Syndrome
|
0.010 |
Biomarker
|
group |
BEFREE |
Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome.
|
10952478 |
2000 |
|
Acute leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
No association between cytochrome P450 2D6 gene polymorphism and risk of acute leukemia: evidence based on a meta-analysis.
|
24112176 |
2013 |
|
Acute leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia.
|
11037802 |
2000 |
|
Agnosia for Pain
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This study investigated the influence of human cytochrome P450 2D6 (CYP2D6) gene polymorphism in gastric cancer (GC) patients to understand the pharmacogenomic basis for patient response to postoperative fentanyl analgesia.
|
25825958 |
2015 |
|
Agranulocytosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6.
|
11147929 |
2000 |
|
Alzheimer's Disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to examine the genetic polymorphism in cytochrome P450 2D6 (CYP2D6) and glutathione S-transferases pi 1 (GSTP1) with respect to organochlorine pesticides (OCPs) and metals in AD.
|
24584466 |
2014 |
|
Alzheimer's Disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
To evaluate the influence of the single nucleotide polymorphism rs1080985 in the cytochrome P450 2D6 (CYP2D6) gene on the efficacy of donepezil in patients with mild to moderate Alzheimer disease (AD).
|
19738170 |
2009 |
|
Alzheimer's Disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.
|
20859244 |
2011 |
|
Amelogenesis Imperfecta, Type IB
|
0.010 |
Biomarker
|
disease |
BEFREE |
Liver Kidney Microsomal autoantibody type 1(LKM1) directed to cytochrome P4502D6 (CYP2D6) characterises autoimmune hepatitis type-2 (AIH-2), but is also found in a proportion of chronic hepatitis C virus (HCV) infected patients, CYP2D6252-271 being a major B- cell autoepitope.
|
15000871 |
2004 |
|
Anemia, Sickle Cell
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.
|
23619115 |
2013 |
|
Ankylosing spondylitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Previous linkage and association studies have suggested the presence of a susceptibility gene for AS close to, or within, the cytochrome P450 2D6 gene (CYP2D6, debrisoquine hydroxylase) located at chromosome 22q13.1.
|
10861282 |
2000 |
|
atrial fibrillation new onset
|
0.010 |
Biomarker
|
disease |
BEFREE |
In a discovery cohort of 563 individuals from the Perioperative Genetics and Safety Outcomes Study (PEGASUS), using a covariate-adjusted logistic regression analysis, we tested 492 single-nucleotide polymorphisms (SNPs) in 10 candidate genes of the adrenergic signaling pathway and cytochrome P450 2D6 for association with postoperative AF despite perioperative BB therapy.
|
25049040 |
2014 |
|
Attention deficit hyperactivity disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
Atomoxetine is a treatment for attention-deficit/hyperactivity disorder and is primarily eliminated via cytochrome P4502D6 (CYP2D6).
|
12621383 |
2003 |
|
Attention deficit hyperactivity disorder
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Ten out of 100 children treated for attention deficit hyperactivity disorder with standard doses of atomoxetine were selected by a neurologist for cytochrome P450 2D6 and cytochrome P450 2C19 genotyping, based on late response (>9 weeks) and adverse effects (gastrointestinal problems, sleeping disorders, malaise, inactivity, and mood instabilities).
|
20691935 |
2010 |
|
Attention deficit hyperactivity disorder
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Atomoxetine, which is indicated for treatment of attention-deficit hyperactivity disorder (ADHD), is predominantly metabolized by genetically polymorphic cytochrome P450 2D6 (CYP2D6).
|
25919121 |
2015 |
|
Attention deficit hyperactivity disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
To determine whether physicians can adequately titrate atomoxetine without knowing genotype status for hepatic cytochrome P450 2D6, we pooled data from two open-label studies of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder.
|
17698328 |
2008 |
|
Autism Spectrum Disorders
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To investigate the effect of the Taq1A variant in the Dopamine D2 receptor gene (DRD2) and common functional genetic variants in the cytochrome P450 2D6 gene (CYP2D6) on prolactin levels in risperidone-treated boys with autism spectrum disorders and disruptive behavior disorders.
|
23851570 |
2013 |
|
Autoimmune Chronic Hepatitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
The hallmark of type 2 AIH is the generation of liver kidney microsomal-1 (LKM-1) autoantibodies, which predominantly react to cytochrome P450 2D6 (CYP2D6).
|
21795021 |
2011 |
|
Autoimmune Chronic Hepatitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
|
Autoimmune Chronic Hepatitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
The liver-kidney 'microsomal' autoantigen reactive with cytochrome P450 2D6 distinguishes two serological types of AIH that appear pathogenetically distinct.
|
21072544 |
2011 |
|
Autoimmune hepatitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
The hallmark of type 2 AIH is the generation of liver kidney microsomal-1 (LKM-1) autoantibodies, which predominantly react to cytochrome P450 2D6 (CYP2D6).
|
21795021 |
2011 |
|
Autoimmune hepatitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
The liver-kidney 'microsomal' autoantigen reactive with cytochrome P450 2D6 distinguishes two serological types of AIH that appear pathogenetically distinct.
|
21072544 |
2011 |
|
Autoimmune hepatitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
|
Autoimmune hepatitis type 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
Liver Kidney Microsomal autoantibody type 1(LKM1) directed to cytochrome P4502D6 (CYP2D6) characterises autoimmune hepatitis type-2 (AIH-2), but is also found in a proportion of chronic hepatitis C virus (HCV) infected patients, CYP2D6252-271 being a major B- cell autoepitope.
|
15000871 |
2004 |